Zobrazeno 1 - 10
of 149
pro vyhledávání: '"E. V. Orlova"'
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 12, Iss 4, Pp 59-69 (2023)
Introduction. Nowadays liquid combined therapeutic and prophylactic bacteriophages produced by various manufacturers are widely used. In order to expand the Russian market with highly effective antibacterial phagopreparations it is urgent to develop
Externí odkaz:
https://doaj.org/article/fb98514446ec42c4bcbc7bf04531c595
Publikováno v:
Биопрепараты: Профилактика, диагностика, лечение, Vol 23, Iss 3-1, Pp 422-430 (2023)
Scientific relevance. The issue of antimicrobial resistance has acquired global significance, urging the search for and use of alternative antibacterial agents to treat infectious diseases. In particular, this situation prompts wider use of biotechno
Externí odkaz:
https://doaj.org/article/17533a9b720f4815a26a7b511c9625c0
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 22, Iss 9 (2023)
Aim. To identify the characteristic features of patients after ischemic stroke (IS), probably associated with spontaneous dissection of the extracranial sections of carotid and vertebral arteries, and compare such patients with persons with IS of oth
Externí odkaz:
https://doaj.org/article/30ebde59afbb4f5cbd8449b38ba1f58a
Autor:
S. M. Mukhina, E. V. Orlova
Publikováno v:
Реальная клиническая практика: данные и доказательства, Vol 2, Iss 2, Pp 1-7 (2022)
This article focuses on patient-reported outcomes (PROs) and their role in decision making in patient-centred healthcare. Let»s look at how PRO can be used in clinical trials, to evaluate the effectiveness of treatment, to validate a claim on a prod
Externí odkaz:
https://doaj.org/article/e0040a412a6b44b596becf504c21f120
Autor:
D. B. Kuznetsov, A. Yu. Mironov, V. A. Neschislyaev, I. L. Volkhin, A. M. Korolyuk, E. V. Orlova, A. D. Shilina
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 10, Iss 4, Pp 72-80 (2021)
Introduction. E. coli strains are the main microorganisms used for the production of a number of important biopharmaceutical products. There are no natural sources of microwave radiation on Earth, as it is absorbed by the upper atmosphere. No one dou
Externí odkaz:
https://doaj.org/article/823b69be42af4ee9be68da7cdf61c58d
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 0, Iss 3, Pp 90-93 (2019)
The present article describes the biochemical mechanisms and the possibility of nucleotides and nucleosides substances naturally produced (i.e. Saccharomyces cerevisiae and others) medicine application in field of correction of pathologically altered
Externí odkaz:
https://doaj.org/article/9197f1b47cb144a69f9cd7a768425707
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 0, Iss 4, Pp 248-255 (2019)
In the present paper some immunological effects on T- and B-cell immunity of a new drug Vitanam - selective activator of Ca-dependent NO-synthase were shown on the animal model.
Externí odkaz:
https://doaj.org/article/d66b6cbd44a1441b99e38d46269e54a1
Autor:
E. S. Kokareva, V. V. Morozov, Ya. M. Stanishevskiy, M. A. Zhuravleva, N. V. Nozdryukhina, V. S. Orlova, E. V. Orlova
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 0, Iss 4, Pp 23-28 (2019)
The article presents information on the structure, classification and functions of NO-synthases. The main inhibitors of the enzyme, as well as their mechanisms of action, are considered. Among the substances activating the activity of the enzyme, spe
Externí odkaz:
https://doaj.org/article/fbc371ce5a74449080c7d2075e08cf72
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 0, Iss 4, Pp 244-246 (2019)
The effect of a new drug - selective activator of Ca-dependent NO-synthase on the processes of hemostasis in norm and type 2 diabetes in laboratory animals is shown in this paper.
Externí odkaz:
https://doaj.org/article/4032b3db6fc64f968b8945bb306072f9
Autor:
D. E. Karateev, E. V. Orlova
Publikováno v:
Медицинский совет, Vol 0, Iss 1S, Pp 90-96 (2017)
According to the literature, Leflunomide is comparable in efficacy and safety with methotrexate, including patients with early rheumatoid arthritis (RA). The drug continues to play an important role in the treatment of patients with early RA and may
Externí odkaz:
https://doaj.org/article/7cf3aec2c7c64a539d9882bd52f3aaf6